Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04703166 · ClinicalTrials.gov registry record
Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
A clinical trial of Atrial Fibrillation, sponsored by Tulane University School of Medicine.
- Recruiting
- Registry status
- 360
- Enrollment target
- 1
- Study location
NCT04703166 is a study of Atrial Fibrillation that is actively recruiting participants, run by Tulane University School of Medicine. The registered enrollment target is 360 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04703166, a study of Atrial Fibrillation, is actively recruiting participants, sponsored by Tulane University School of Medicine.
- RECRUITING
- Registry status
- 360 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.
Conditions Studied
Interventions
- DEVICE Samsung Galaxy Watch Active2
Study Locations (1)
Louisiana
- Tulane University School of Medicine - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04703166
The ClinicalTrials.gov registry entry for NCT04703166 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The listed sponsor is Tulane University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Samsung Galaxy Watch Active2 is the first listed.
NCT04703166 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT04703166 about?
NCT04703166 is a clinical study titled "Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.". To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.
What is the current status of trial NCT04703166?
This trial is currently recruiting. The enrollment target is 360 participants. The study started on 2025-04-08. Estimated completion is 2027-12.
What conditions does trial NCT04703166 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT04703166?
The interventions under investigation include: Samsung Galaxy Watch Active2 (DEVICE).
Who is sponsoring clinical trial NCT04703166?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04703166 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.